You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Infections
  5. Hepatitis

Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B

  • Technology appraisal guidance
  • Reference number: TA96
  • Published:  22 February 2006
  • Guidance
  • Tools and resources
  • Information for the public
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 Clinical need and practice
  • 3 The technologies
  • 4 Evidence and interpretation
  • 5 Recommendations for further research
  • 6 Implementation and audit
  • 7 Appraisal Committee members and NICE project team
  • 8 Sources of evidence considered by the Committee
  • Appendix A Detail on criteria for audit of the use of adefovir dipivoxil and peginterferon alfa-2a for chronic hepatitis B
  • Update information

1 Recommendations

This guidance does not apply to people with chronic hepatitis B known to be co‑infected with hepatitis C, hepatitis D or HIV.

1.1

Peginterferon alfa-2a is recommended as an option for the initial treatment of adults with chronic hepatitis B (HBeAg-positive or HBeAg-negative), within its licensed indications.

1.2

This recommendation has been replaced by recommendation 1.5.13 in NICE's guideline on hepatitis B (chronic): diagnosis and management.

1.3

This recommendation has been replaced by recommendation 1.5.14 in NICE's guideline on hepatitis B (chronic): diagnosis and management.

1.4

This recommendation has been replaced by recommendation 1.5.15 in NICE's guideline on hepatitis B (chronic): diagnosis and management.


Next page 2 Clinical need and practice Previous page Overview
Back to top